Novartis AG has agreed to acquire biotechnology firm Excellergy Inc. for up to $2 billion, a move that will enhance its product offerings in the treatment of food allergies and other immune-related disorders. The Swiss pharmaceutical company stated that the transaction includes upfront and milestone payments and is expected to finalize in the second half of this year, pending regulatory approvals and other customary closing conditions. The centerpiece of the acquisition is Excellergy's innovative drug candidate, Exl-111. Designed as a novel trifunctional effector cell response inhibitor (ECRI), Exl-111 specifically targets the immunoglobulin E (IgE)-mediated immune pathway. IgE is a key factor in the development of various allergic conditions, triggering exaggerated immune responses to typically harmless substances. Compared to existing anti-IgE therapies, Exl-111 is engineered to provide more potent signal suppression, enabling faster and more profound blockade of allergic reactions. Currently in early-stage clinical trials, Exl-111 has the potential to become a treatment for multiple conditions, including food allergies, chronic spontaneous urticaria, chronic inducible urticaria, and allergic asthma. From an industry perspective, the addition of Excellergy will provide Novartis with a more differentiated portfolio in the allergy therapeutics space. As the global incidence of allergic diseases continues to rise, demand is growing for longer-acting and safer biologic treatments. If Exl-111 advances successfully through later-stage clinical development and gains regulatory approval, it is expected to create synergies with Novartis’s existing immunology pipeline. It is worth noting that, amid increasing generic competition for several of its established blockbuster drugs, Novartis has been actively pursuing acquisitions to bolster its research and development pipeline. This strategy has contributed to the company’s projection of its first profit decline in at least six years. Just one week prior to this agreement, Novartis announced the acquisition of Synnovation Therapeutics for $3 billion to strengthen its oncology assets. Additionally, in October of last year, the company revealed one of its largest investments—the $12 billion acquisition of Avidity Biosciences—followed by several other transactions focused on allergy treatments and breast cancer therapies.
Comments